Literature DB >> 33579720

Outcomes of Clostridioides difficile infection in adult cancer and non-cancer patients hospitalised in a tertiary hospital: a prospective cohort study.

Bojana Milenković1, Vesna Šuljagić2,3, Aneta Perić4,2, Viktorija Dragojević-Simić2,5, Olivera Tarabar2,6, Milomir Milanović2,7, Vesna Putić4,2, Diana Tomić8, Branislava Miljković9, Sandra Vezmar Kovačević9.   

Abstract

BACKGROUND: Clostridioides difficile infection (CDI) is one of the most common healthcare-associated (HA) infections. Cancer patients, particularly haemato-oncological patients, have an increased risk for CDI due to more risk factors compared with non-cancer patients. The aim of this study was to investigate differences in outcomes associated with HA CDI in patients with solid and haematological malignancies compared with patients with no underlying malignant disease in a tertiary healthcare centre in Serbia.
METHODS: A prospective cohort study was conducted including adult patients diagnosed with an initial episode of HA CDI. Their demographic and clinical characteristics associated with risk factors for CDI were documented. Outcomes such as all-cause 30-day mortality, cure of infection, diarrhoea relaps and recurrence of disease were followed. Patients were assigned to cancer and non-cancer groups. Within the cancer group, patients were divided into the solid tumour subgroup and haematological malignancy subgroup.
RESULTS: During a 7-year period, HA CDI was observed in 28 (5.1%) patients with haematological malignancy, 101 (18.3%) patients with solid tumours and 424 (76.7%) non-cancer patients. Older age (OR 1.04, 95% CI 1.02 to 1.07, p<0.001), admission to the intensive care unit (ICU) (OR 2.61, 95% CI 1.37 to 4.95, p=0.003), mechanical ventilation (OR 5.19, 95% CI 2.78 to 9.71, p<0.001) and use of antibiotics prior to CDI (OR 1.04, 95% CI 1.02 to 1.06, p=0.02) were associated with increased mortality. Compared with patients with solid tumours, patients with haematological malignancy were younger (65 vs 57 years, p=0.015), did not require ICU admission (25.0% vs 0%) or mechanical ventilation (8.9% vs 0%) and were treated longer with antibiotics prior to CDI (14 vs 24 days, p=0.002).
CONCLUSIONS: Patients with haematological malignancy were exposed to different risk factors for CDI associated with mortality compared with patients with solid tumours and non-cancer patients. Older age, ICU stay and mechanical ventilation, but not presence or type of cancer, predicted the all-cause 30-day mortality. © European Association of Hospital Pharmacists 2022. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  clinical medicine; controlled clinical trial; drug-related side effects and adverse reactions; education department; gastrointestinal neoplasms; head and neck neoplasms; hematology; hospital; kidney neoplasms; leukemia; microbiology; multiple myeloma; transplantation; urologic neoplasms

Mesh:

Year:  2021        PMID: 33579720      PMCID: PMC8899674          DOI: 10.1136/ejhpharm-2020-002574

Source DB:  PubMed          Journal:  Eur J Hosp Pharm        ISSN: 2047-9956


  44 in total

1.  Is Clostridium difficile infection an increasingly common severe disease in adult intensive care units? A 10-year experience.

Authors:  E Bouza; M Rodríguez-Créixems; L Alcalá; M Marín; V De Egea; F Braojos; P Muñoz; E Reigadas
Journal:  J Crit Care       Date:  2015-02-28       Impact factor: 3.425

Review 2.  The epidemiology of Clostridium difficile infection in patients with cancer.

Authors:  Andrew I T Hebbard; Monica A Slavin; Caroline Reed; Benjamin W Teh; Karin A Thursky; Jason A Trubiano; Leon J Worth
Journal:  Expert Rev Anti Infect Ther       Date:  2016-09-21       Impact factor: 5.091

3.  Cumulative antibiotic exposures over time and the risk of Clostridium difficile infection.

Authors:  Vanessa Stevens; Ghinwa Dumyati; Lynn S Fine; Susan G Fisher; Edwin van Wijngaarden
Journal:  Clin Infect Dis       Date:  2011-07-01       Impact factor: 9.079

4.  Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA).

Authors:  L Clifford McDonald; Dale N Gerding; Stuart Johnson; Johan S Bakken; Karen C Carroll; Susan E Coffin; Erik R Dubberke; Kevin W Garey; Carolyn V Gould; Ciaran Kelly; Vivian Loo; Julia Shaklee Sammons; Thomas J Sandora; Mark H Wilcox
Journal:  Clin Infect Dis       Date:  2018-03-19       Impact factor: 9.079

Review 5.  Emergence of Clostridium difficile-associated disease in North America and Europe.

Authors:  E J Kuijper; B Coignard; P Tüll
Journal:  Clin Microbiol Infect       Date:  2006-10       Impact factor: 8.067

6.  Prognosis of Clostridium difficile infection in adult oncohaematological patients: experience from a large prospective observational study.

Authors:  Isabel Ruiz-Camps; Benito Almirante; Thais Larrainzar-Coghen; Dolors Rodríguez-Pardo; Pere Barba; Juan Aguilar-Company; Virginia Rodríguez; Gloria Roig; Carmen Ferrer
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-08-02       Impact factor: 3.267

7.  Impact of malignancy on Clostridium difficile infection.

Authors:  M S Chung; J Kim; J O Kang; H Pai
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-07-26       Impact factor: 3.267

8.  Incidence and mortality associated with Clostridium difficile infection at a Japanese tertiary care center.

Authors:  Hitoshi Honda; Akinori Yamazaki; Yumiko Sato; Erik R Dubberke
Journal:  Anaerobe       Date:  2013-11-01       Impact factor: 3.331

9.  Evaluating risk factors for Clostridium difficile infection in adult and pediatric hematopoietic cell transplant recipients.

Authors:  Nicole M Boyle; Amalia Magaret; Zach Stednick; Alex Morrison; Susan Butler-Wu; Danielle Zerr; Karin Rogers; Sara Podczervinski; Anqi Cheng; Anna Wald; Steven A Pergam
Journal:  Antimicrob Resist Infect Control       Date:  2015-10-14       Impact factor: 4.887

10.  Clostridium difficile carriage in hospitalized cancer patients: a prospective investigation in eastern China.

Authors:  Wei-Jia Fang; Da-Zhi Jing; Yun Luo; Cai-Yun Fu; Peng Zhao; Jiong Qian; Bing-Ru Tian; Xiao-Gang Chen; Yu-Long Zheng; Yi Zheng; Jing Deng; Wei-Hua Zou; Xue-Ren Feng; Fan-Long Liu; Xiao-Zhou Mou; Shu-Sen Zheng
Journal:  BMC Infect Dis       Date:  2014-09-29       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.